Terry O’Reilly

Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts

Michaela Kneissel, Ngoc-Hong Luong-Nguyen, Myma Baptist et al. · Bone · 2004 · 161 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +16

Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK

Linh T. Nguyen, Jaymes Holland, Dale Miles et al. · The Journal of Clinical Pharmacology · 2015 · 75 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +17

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

Terry O’Reilly, Paul M.J. McSheehy, Markus Wartmann et al. · Anti-Cancer Drugs · 2010 · 68 citations

Medicine, Oncology, Pharmacology +15

First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers

Jonathan C. Fox, Jennifer Hellawell, Satish Rao et al. · Clinical Pharmacology in Drug Development · 2019 · 64 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +13

Inhibition of fatty acid synthase with <scp>FT‐4101</scp> safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

Carine Beysen, Patricia Schroeder, Eric Wu et al. · Diabetes Obesity and Metabolism · 2020 · 53 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15